Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kaoru Nakazato is active.

Publication


Featured researches published by Kaoru Nakazato.


American Journal of Cardiology | 1995

Gender-related differences on signal-averaged electrocardiograms in healthy subjects

Yuji Nakazato; Yasuro Nakata; Kaoru Nakazato; Takashi Tokano; Masayuki Yasuda; Yasuhiko Ohno; Yoshihisa Matsumoto; Masataka Sumiyoshi; Shunsuke Ogura; Hiroshi Yamaguchi; Toru Iwa

Abstract In conclusion, filtered QRS duration in time-domain analysis of SAEs was influenced by gender and body characteristics in healthy subjects; however, the parameters in spectral turbulence analysis were not.


Pacing and Clinical Electrophysiology | 2004

Dislodgment of an Atrial Screw‐In Pacing Lead 10 Years After Implantation

Takashi Tokano; Yuji Nakazato; Akitoshi Sasaki; Haruyo Yamashita; Yoji Iida; Yasunobu Kawano; Yoriaki Mineda; Kaoru Nakazato; Masayuki Yasuda; Masataka Sumiyoshi; Yasuro Nakata; Hiroyuki Daida

Dislodgment of an atrial screw‐in pacing lead is quite rare. This report describes a rare case of an atrial screw‐in lead dislodgment 10 years after implantation. Although it is an uncommon complication, very late dislodgment can occur postoperatively, and careful follow‐up is necessary. (PACE 2004; 27:264–265)


Journal of Cardiovascular Pharmacology | 2003

What is the optimal increase in resting heart rate with low dose isoproterenol infusion for tilt-induced vasovagal response?

Masataka Sumiyoshi; Haruhiko Abe; Yoriaki Mineda; Takashi Tokano; Masayuki Yasuda; Kaoru Nakazato; Yuji Nakazato; Yasuro Nakata; Hiroyuki Daida

Summary: Isoproterenol is widely used as a provocative medium for vasovagal responses during tilt testing. Dose of isoproterenol infusion is generally titrated empirically by increase in resting heart rate before tilt up. To determine the optimal increase in resting heart rate with isoproterenol for tilt‐induced vasovagal responses, we studied 97 consecutive patients with unexplained syncope. After the end of a negative baseline tilt (80° for 30 min), the isoproterenol tilt was performed using one of two protocols: two‐stage isoproterenol‐tilt protocol, with doses of 0.01 and 0.02 μg/kg per min for 10 min each, or one‐stage isoproterenol‐tilt protocol, with a dose of 1 or 2 μg/min for 10 min. The resting heart rate increase was defined as a percentage increase in the resting heart rate after isoproterenol infusion, compared to the baseline heart rate before the tilt test. In 117 tilt procedures, 28 (93%) of the 30 positive responses occurred with a resting heart rate increase of ≥21%. With the resting heart rate increase of 60 and 100%, 18 (60%) and 27 (90%) positive responses were observed, respectively. In conclusion, the minimum resting heart rate increase of ≥21% was required to provoke a vasovagal response during subsequent isoproterenol‐tilt (80° for 10 min). Preferably, heart rate should be increased to 60‐100% by isoproterenol titration before tilting.


Pacing and Clinical Electrophysiology | 1999

Runaway Pacemaker Caused by a Stuck Accelerometer

Yuji Nakazato; Yasuro Nakata; Masayuki Yasuda; Kaoru Nakazato; Mikio Tanaka; Masataka Sumiyoshi; Hidehiko Sakurai; Hiroshi Yamaguchi

We report a case of runaway pacemaker with a ventricular pacing rate of 190 beats/min. The runaway occurred when the accelerometer became stuck due to the magnet application during VVIR pacing. Runaways in modern pacemakers are particularly rare, but they do still occur. The best solution for this phenomenon is generator replacement.


Clinical Pharmacology & Therapeutics | 2005

Efficacy and safety of controlled-release isosorbide-5-mononitrate for patients with stable effort angina pectoris: A randomized, double-blind, placebo-controlled study

Kazunori Shimada; Satoshi Sunayama; Kaoru Nakazato; Hitoshi Satoh; Hiroyuki Daida

A major limitation of the use of nitrates is the development of “nitrate tolerance”. The widely accepted treatment of preventing tolerance is to provide a period of “low nitrate interval”. Then, a new controlled‐release isosorbide‐5‐mononitrate (I‐CR) has been developed.


Circulation | 2005

Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation.

Yuji Nakazato; Masayuki Yasuda; Akitoshi Sasaki; Youji Iida; Yasunobu Kawano; Kaoru Nakazato; Takashi Tokano; Yoriaki Mineda; Masataka Sumiyoshi; Yasuro Nakata; Hiroyuki Daida


Circulation | 2006

Clinical Evaluation of Adverse Effects During Bepridil Administration for Atrial Fibrillation and Flutter

Masayuki Yasuda; Yuji Nakazato; Akitoshi Sasaki; Yasunobu Kawano; Kaoru Nakazato; Takashi Tokano; Hiroyuki Daida


Japanese Heart Journal | 1997

Safety and Efficacy of Oral Flecainide Acetate in Patients with Cardiac Arrhythmias.

Yuji Nakazato; Yasuro Nakata; Masayuki Yasuda; Kaoru Nakazato; Masataka Sumiyoshi; Shunsuke Ogura; Hiroshi Yamaguchi


Internal Medicine | 2005

Ventricular fibrillation refractory to ICD therapy.

Masayuki Yasuda; Yuji Nakazato; Akitoshi Sasaki; Yasunobu Kawano; Kaoru Nakazato; Takashi Tokano; Hiroyuki Daida


Japanese Circulation Journal-english Edition | 1999

Acute Performance of Steroid-Eluting Screw-In Leads for Atrial Free Wall Pacing

Yuji Nakazato; Yasuro Nakata; Yoriaki Mineta; Kaoru Nakazato; Masayuki Yasuda; Masataka Sumiyoshi; Hiroshi Yamaguchi

Collaboration


Dive into the Kaoru Nakazato's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroshi Yamaguchi

National Institute of Advanced Industrial Science and Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge